Search
News & Events
State Government boost for The Kids researchThe Kids Research Institute Australia researchers have been awarded five of eight State Government awards designed to help cover the hidden costs of conducting research.
Telethon Kids has joined scientists around the world in the fight against COVID-19 and is committed to helping families stay safe and well during this crisis.
News & Events
The Kids researchers lead national trial to fight sepsis in premature infantsThe Kids Research Institute Australia researchers will lead a new national clinical trial (COSI-2) to determine whether topical coconut oil can reduce late onset sepsis in extremely preterm infants.
Research Theme
Infectious DiseasesAims to prevent, diagnose, and treat infectious diseases, with a strong focus on developing effective vaccines and improving immunity across populations. This theme addresses both emerging and persistent infections that impact children's health worldwide.
Research
Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of ageFrom 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.
Research
Whooping CoughWhooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.
News & Events
Study suggests flu vaccine may take edge off RSV casesA The Kids Research Institute Australia study has suggested the seasonal flu vaccine for children could also protect them from respiratory syncytial virus (RSV), with the dual benefit easing pressure on hospitals.
This tool is designed to help current and future parents and caregivers as well as health care providers. It is currently based on the 2025 Western Australian RSV immunisation program.
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
FluBubs: Safety and immunogenicity of Early Quadrivalent Influenza VaccineChristopher Tobias Blyth Kollmann MBBS (Hons) DCH FRACP FRCPA PhD PhD, M.D., SFUW Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;